Global Myelodysplastic Syndrome Market Research Report 2019-2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 110

Report ID: 12265

Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells.[2] Early on there are typically no symptoms.Later symptoms may include feeling tired, shortness of breath, easy bleeding, or frequent infections.[2] Some types may develop into acute myeloid leukemia.
The presence of diagnostic tools is the key driver for the growth of this market. Diagnosis techniques like blood count, peripheral blood smear test, microscopic exams, cytochemistry, flow cytometry and immunotherapy, cytogenetics, FISH, and PCR help in the detection of MDS. Consequently, these diagnostic tools are expected to have a positive impact on the usage of drugs for people suffering from MDS.

The global Myelodysplastic Syndrome market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Myelodysplastic Syndrome volume and value at global level, regional level and company level. From a global perspective, this report represents overall Myelodysplastic Syndrome market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Celgene
Novartis
Otsuka
Actinium Pharmaceuticals
Acceleron Pharma
Bellicum Pharmaceuticals
Cornerstone Pharmaceuticals
CTI BioPharma
Onconova Therapeutics
Strategia Therapeutics
KaloBios Pharmaceuticals
Kiadis Pharma
Mirati Therapeutics
Astex
Celator Pharmaceuticals
Eli-lilly
Sunesis Pharmaceuticals
Targazyme
Gamida Cell
GlaxoSmithKline
Sumitomo Dainippon Pharma
TetraLogic Pharmaceuticals

Segment by Regions
North America
Europe
China
Japan

Segment by Type
Alkylating Agents
Cytotoxic Antibiotics
Topoisomerase Inhibitors
Others

Segment by Application
Hospital
Clinic

Table of Contents

Executive Summary
1 Myelodysplastic Syndrome Market Overview
1.1 Product Overview and Scope of Myelodysplastic Syndrome
1.2 Myelodysplastic Syndrome Segment by Type
1.2.1 Global Myelodysplastic Syndrome Production Growth Rate Comparison by Type (2014-2025)
1.2.2 Alkylating Agents
1.2.3 Cytotoxic Antibiotics
1.2.4 Topoisomerase Inhibitors
1.2.5 Others
1.3 Myelodysplastic Syndrome Segment by Application
1.3.1 Myelodysplastic Syndrome Consumption Comparison by Application (2014-2025)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Myelodysplastic Syndrome Market by Region
1.4.1 Global Myelodysplastic Syndrome Market Size Region
1.4.2 North America Status and Prospect (2014-2025)
1.4.3 Europe Status and Prospect (2014-2025)
1.4.4 China Status and Prospect (2014-2025)
1.4.5 Japan Status and Prospect (2014-2025)
1.5 Global Myelodysplastic Syndrome Market Size
1.5.1 Global Myelodysplastic Syndrome Revenue (2014-2025)
1.5.2 Global Myelodysplastic Syndrome Production (2014-2025)

2 Global Myelodysplastic Syndrome Market Competition by Manufacturers
2.1 Global Myelodysplastic Syndrome Production Market Share by Manufacturers (2014-2019)
2.2 Global Myelodysplastic Syndrome Revenue Share by Manufacturers (2014-2019)
2.3 Global Myelodysplastic Syndrome Average Price by Manufacturers (2014-2019)
2.4 Manufacturers Myelodysplastic Syndrome Production Sites, Area Served, Product Types
2.5 Myelodysplastic Syndrome Market Competitive Situation and Trends
2.5.1 Myelodysplastic Syndrome Market Concentration Rate
2.5.2 Myelodysplastic Syndrome Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion

3 Global Myelodysplastic Syndrome Production Market Share by Regions
3.1 Global Myelodysplastic Syndrome Production Market Share by Regions
3.2 Global Myelodysplastic Syndrome Revenue Market Share by Regions (2014-2019)
3.3 Global Myelodysplastic Syndrome Production, Revenue, Price and Gross Margin (2014-2019)
3.4 North America Myelodysplastic Syndrome Production
3.4.1 North America Myelodysplastic Syndrome Production Growth Rate (2014-2019)
3.4.2 North America Myelodysplastic Syndrome Production, Revenue, Price and Gross Margin (2014-2019)
3.5 Europe Myelodysplastic Syndrome Production
3.5.1 Europe Myelodysplastic Syndrome Production Growth Rate (2014-2019)
3.5.2 Europe Myelodysplastic Syndrome Production, Revenue, Price and Gross Margin (2014-2019)
3.6 China Myelodysplastic Syndrome Production (2014-2019)
3.6.1 China Myelodysplastic Syndrome Production Growth Rate (2014-2019)
3.6.2 China Myelodysplastic Syndrome Production, Revenue, Price and Gross Margin (2014-2019)
3.7 Japan Myelodysplastic Syndrome Production (2014-2019)
3.7.1 Japan Myelodysplastic Syndrome Production Growth Rate (2014-2019)
3.7.2 Japan Myelodysplastic Syndrome Production, Revenue, Price and Gross Margin (2014-2019)

4 Global Myelodysplastic Syndrome Consumption by Regions
4.1 Global Myelodysplastic Syndrome Consumption by Regions
4.2 North America Myelodysplastic Syndrome Consumption (2014-2019)
4.3 Europe Myelodysplastic Syndrome Consumption (2014-2019)
4.4 China Myelodysplastic Syndrome Consumption (2014-2019)
4.5 Japan Myelodysplastic Syndrome Consumption (2014-2019)

5 Global Myelodysplastic Syndrome Production, Revenue, Price Trend by Type
5.1 Global Myelodysplastic Syndrome Production Market Share by Type (2014-2019)
5.2 Global Myelodysplastic Syndrome Revenue Market Share by Type (2014-2019)
5.3 Global Myelodysplastic Syndrome Price by Type (2014-2019)
5.4 Global Myelodysplastic Syndrome Production Growth by Type (2014-2019)

6 Global Myelodysplastic Syndrome Market Analysis by Applications
6.1 Global Myelodysplastic Syndrome Consumption Market Share by Application (2014-2019)
6.2 Global Myelodysplastic Syndrome Consumption Growth Rate by Application (2014-2019)

7 Company Profiles and Key Figures in Myelodysplastic Syndrome Business
7.1 Celgene
7.1.1 Celgene Myelodysplastic Syndrome Production Sites and Area Served
7.1.2 Myelodysplastic Syndrome Product Introduction, Application and Specification
7.1.3 Celgene Myelodysplastic Syndrome Production, Revenue, Price and Gross Margin (2014-2019)
7.1.4 Main Business and Markets Served
7.2 Novartis
7.2.1 Novartis Myelodysplastic Syndrome Production Sites and Area Served
7.2.2 Myelodysplastic Syndrome Product Introduction, Application and Specification
7.2.3 Novartis Myelodysplastic Syndrome Production, Revenue, Price and Gross Margin (2014-2019)
7.2.4 Main Business and Markets Served
7.3 Otsuka
7.3.1 Otsuka Myelodysplastic Syndrome Production Sites and Area Served
7.3.2 Myelodysplastic Syndrome Product Introduction, Application and Specification
7.3.3 Otsuka Myelodysplastic Syndrome Production, Revenue, Price and Gross Margin (2014-2019)
7.3.4 Main Business and Markets Served
7.4 Actinium Pharmaceuticals
7.4.1 Actinium Pharmaceuticals Myelodysplastic Syndrome Production Sites and Area Served
7.4.2 Myelodysplastic Syndrome Product Introduction, Application and Specification
7.4.3 Actinium Pharmaceuticals Myelodysplastic Syndrome Production, Revenue, Price and Gross Margin (2014-2019)
7.4.4 Main Business and Markets Served
7.5 Acceleron Pharma
7.5.1 Acceleron Pharma Myelodysplastic Syndrome Production Sites and Area Served
7.5.2 Myelodysplastic Syndrome Product Introduction, Application and Specification
7.5.3 Acceleron Pharma Myelodysplastic Syndrome Production, Revenue, Price and Gross Margin (2014-2019)
7.5.4 Main Business and Markets Served
7.6 Bellicum Pharmaceuticals
7.6.1 Bellicum Pharmaceuticals Myelodysplastic Syndrome Production Sites and Area Served
7.6.2 Myelodysplastic Syndrome Product Introduction, Application and Specification
7.6.3 Bellicum Pharmaceuticals Myelodysplastic Syndrome Production, Revenue, Price and Gross Margin (2014-2019)
7.6.4 Main Business and Markets Served
7.7 Cornerstone Pharmaceuticals
7.7.1 Cornerstone Pharmaceuticals Myelodysplastic Syndrome Production Sites and Area Served
7.7.2 Myelodysplastic Syndrome Product Introduction, Application and Specification
7.7.3 Cornerstone Pharmaceuticals Myelodysplastic Syndrome Production, Revenue, Price and Gross Margin (2014-2019)
7.7.4 Main Business and Markets Served
7.8 CTI BioPharma
7.8.1 CTI BioPharma Myelodysplastic Syndrome Production Sites and Area Served
7.8.2 Myelodysplastic Syndrome Product Introduction, Application and Specification
7.8.3 CTI BioPharma Myelodysplastic Syndrome Production, Revenue, Price and Gross Margin (2014-2019)
7.8.4 Main Business and Markets Served
7.9 Onconova Therapeutics
7.9.1 Onconova Therapeutics Myelodysplastic Syndrome Production Sites and Area Served
7.9.2 Myelodysplastic Syndrome Product Introduction, Application and Specification
7.9.3 Onconova Therapeutics Myelodysplastic Syndrome Production, Revenue, Price and Gross Margin (2014-2019)
7.9.4 Main Business and Markets Served
7.10 Strategia Therapeutics
7.10.1 Strategia Therapeutics Myelodysplastic Syndrome Production Sites and Area Served
7.10.2 Myelodysplastic Syndrome Product Introduction, Application and Specification
7.10.3 Strategia Therapeutics Myelodysplastic Syndrome Production, Revenue, Price and Gross Margin (2014-2019)
7.10.4 Main Business and Markets Served
7.11 KaloBios Pharmaceuticals
7.12 Kiadis Pharma
7.13 Mirati Therapeutics
7.14 Astex
7.15 Celator Pharmaceuticals
7.16 Eli-lilly
7.17 Sunesis Pharmaceuticals
7.18 Targazyme
7.19 Gamida Cell
7.20 GlaxoSmithKline
7.21 Sumitomo Dainippon Pharma
7.22 TetraLogic Pharmaceuticals

8 Myelodysplastic Syndrome Manufacturing Cost Analysis
8.1 Myelodysplastic Syndrome Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Price Trend of Key Raw Materials
8.1.3 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Myelodysplastic Syndrome
8.4 Myelodysplastic Syndrome Industrial Chain Analysis

9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.2 Myelodysplastic Syndrome Distributors List
9.3 Myelodysplastic Syndrome Customers

10 Market Dynamics
10.1 Market Trends
10.2 Opportunities
10.3 Market Drivers
10.4 Challenges
10.5 Influence Factors

11 Global Myelodysplastic Syndrome Market Forecast
11.1 Global Myelodysplastic Syndrome Production, Revenue Forecast
11.1.1 Global Myelodysplastic Syndrome Production Growth Rate Forecast (2019-2025)
11.1.2 Global Myelodysplastic Syndrome Revenue and Growth Rate Forecast (2019-2025)
11.1.3 Global Myelodysplastic Syndrome Price and Trend Forecast (2019-2025)
11.2 Global Myelodysplastic Syndrome Production Forecast by Regions (2019-2025)
11.2.1 North America Myelodysplastic Syndrome Production, Revenue Forecast (2019-2025)
11.2.2 Europe Myelodysplastic Syndrome Production, Revenue Forecast (2019-2025)
11.2.3 China Myelodysplastic Syndrome Production, Revenue Forecast (2019-2025)
11.2.4 Japan Myelodysplastic Syndrome Production, Revenue Forecast (2019-2025)
11.3 Global Myelodysplastic Syndrome Consumption Forecast by Regions (2019-2025)
11.3.1 North America Myelodysplastic Syndrome Consumption Forecast (2019-2025)
11.3.2 Europe Myelodysplastic Syndrome Consumption Forecast (2019-2025)
11.3.3 China Myelodysplastic Syndrome Consumption Forecast (2019-2025)
11.3.4 Japan Myelodysplastic Syndrome Consumption Forecast (2019-2025)
11.4 Global Myelodysplastic Syndrome Production, Revenue and Price Forecast by Type (2019-2025)
11.5 Global Myelodysplastic Syndrome Consumption Forecast by Application (2019-2025)

12 Research Findings and Conclusion

13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer